UnknownPHASE1, PHASE2NCT03669614

SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

Studying Cystic fibrosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Aridis Pharmaceuticals, Inc.
Principal Investigator
Hasan S Jafri, MD, FAAP
Aridis Pharmaceuticals, Inc.
Intervention
Inhaled AR-501(drug)
Enrollment
102 enrolled
Eligibility
18-49 years · All sexes
Timeline
2018 – 2023

Study locations (25)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03669614 on ClinicalTrials.gov

Other trials for Cystic fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Cystic fibrosis →

← Back to all trials